DAWA LIMITED

What DAWA LIMITED does

DAWA Limited is a UK-based privately held independent generic pharmaceutical Marketing Authorisations Holder (MAH) founded in 2004 and headquartered in Harrow, England. The company holds over 120 Marketing Authorisations granted by the Medicines and Healthcare products Regulatory Agency (MHRA), with an additional 40 licences under development or application. Its portfolio spans tablets, capsules, oral suspensions, oral solutions, toothpastes, eye drops, and injections, with named products including Glycopyrronium Bromide Tablets (1mg and 2mg, Product Licences PL 30684/0125 and PL 30684/0126), Co-trimoxazole 80mg tablets, and Haloperidol 5mg/ml oral solution.

DAWA operates an asset-light manufacturing model, partnering with EU GMP-approved Contract Manufacturing Organisations to produce its licensed formulations rather than owning production facilities. An in-house regulatory department handles Marketing Authorisation applications and dossier maintenance. All UK distribution is channelled exclusively through sister company Drugsrus Limited, which holds the Manufacturers Import Authorisation (MIA) and supplies all major UK wholesalers, medium-sized wholesalers, and the NHS.

The company employs approximately 17 people and generates revenue through B2B sales of generic pharmaceutical products in the UK, supplemented by in-licensing and out-licensing opportunities for pharmaceutical dossiers. No revenue figures, pricing details, management team information, or external institutional ownership are publicly disclosed. The company is privately held with no disclosed venture capital or private equity backing.

Name

DAWA LIMITED

Legal name

Dawa Generics Limited

Website

https://dawagenerics.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

DAWA Limited is a UK-based private generic pharmaceutical Marketing Authorisations Holder with over 120 MHRA-granted licences. The asset-light firm partners with EU GMP-approved CMOs and distributes exclusively via sister company Drugsrus Limited to UK wholesalers and the NHS.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Generic pharmaceuticals
• Marketing authorisations
• MHRA licensing
• Contract manufacturing
• Pharmaceutical distribution

Headquarters

HQ city

Harrow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D

Revenue model

1. Generic Pharmaceutical Sales: DAWA generates revenue through the sale of generic pharmaceutical products. They hold over 120 Marketing Authorisations granted by MHRA for generic medicines including tablets, capsules, oral suspensions, oral solutions, toothpastes, eye drops, and injections. Products are distributed via their sister company Drugsrus Limited to the UK market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

DAWA Limited is a UK Marketing Authorisations Holder holding MHRA licences for 120+ generic pharmaceutical products, with approximately 40 additional products under development. Manufacturing is carried out via EU GMP-approved Contract Manufacturing Organisations across multiple dosage forms including tablets, capsules, oral suspensions, oral solutions, toothpastes, eye drops, and injections, with UK distribution handled through its sister company Drugsrus Limited to wholesalers and the NHS.

Product overview

DAWA Limited is a UK-based generic pharmaceutical Marketing Authorisations Holder (MAH) operating as a single unified product offering centered on generic medicine licensing and distribution. The portfolio spans over 120 granted MHRA licences plus 40 under development, with individual products including Glycopyrronium Bromide Tablets (1mg and 2mg), Co-trimoxazole, and Haloperidol 5mg/Ml. The company facilitates manufacturing of multiple formulations (tablets, capsules, oral suspensions, oral solutions, toothpastes, eye drops, injections) through EU GMP approved CMOs, with distribution handled by sister company Drugsrus Limited. Regulatory services are managed in-house.

Differentiator

Problem solved

Functional benefit

Products and services

• Glycopyrronium Bromide Tablets Glycopyrronium Bromide Tablets supplied in 1mg and 2mg strengths as a licensed UK generic anticholinergic medicine, intended for wholesalers and the NHS distributing into UK pharmacy channels.
• Co-trimoxazole 80mg Tablets Co-trimoxazole 80mg Tablets supplied as a licensed UK generic antibiotic for wholesalers and the NHS distributing into UK pharmacy channels.
• Haloperidol 5mg/ml Oral Solution Haloperidol 5mg/ml Oral Solution supplied as a licensed UK generic antipsychotic medicine in liquid dosage form for wholesalers and the NHS distributing into UK pharmacy channels.
• MHRA-Licensed Generic Medicines Portfolio A portfolio of 120+ MHRA-licensed generic pharmaceutical products across multiple dosage forms (tablets, capsules, oral suspensions, oral solutions, toothpastes, eye drops, injections), supplied to UK wholesalers and the NHS through sister company Drugsrus Limited, with approximately 40 additional products under development.

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Drugsrus LimitedcoreChannel Partner/ Reseller/ DistributorDrugsrus Limited is DAWA's sister company that handles all distribution of pharmaceutical products. It holds the Manufacturers Import Authorisation (MIA) and releases medicines for sale under each Marketing Authorisation. Drugsrus has extensive access to the UK market, supplying all major wholesalers, medium-sized wholesalers, and the NHS.
• EU GMP Approved Contract Manufacturing Organisations (CMO)coreStrategic or Co-development PartnerDAWA works with EU GMP approved Contract Manufacturing Organisations to facilitate the manufacture of the full range of formulations including tablets, capsules, oral suspensions, oral solutions, toothpastes, eye drops, and injections.

Scale indicators3 records

Recent moves1 record

Expansion highlights4 records

Direct peers

• Consilient Health: Consilient Health is a UK and Ireland-focused generic and specialty pharmaceutical company that holds MAs and markets products through wholesale channels. Comparable business model to DAWA with a broader European footprint.
• Ennogen Healthcare: Ennogen Healthcare is a UK-based generic pharmaceutical company holding Marketing Authorisations with outsourced manufacturing. Direct competitor in the UK small-cap generic MAH space with similar distribution through UK wholesalers.
• Tillomed Laboratories: Tillomed Laboratories is a UK-based generic pharmaceutical company that holds Marketing Authorisations and distributes through UK wholesale channels. Highly comparable to DAWA in business model (MAH, outsourced manufacturing, UK market focus) and scale.
• Chelonia Healthcare: Chelonia Healthcare is a UK-based specialty generic pharmaceutical company with in-house regulatory and outsourced manufacturing. Closely comparable to DAWA's MAH-with-CMO model and UK distribution focus.
• Bristol Laboratories: Bristol Laboratories is a UK-based generic pharmaceutical MAH that outsources manufacturing and supplies to UK wholesalers and the NHS. Operates a similar virtual pharma model to DAWA with comparable scale and product portfolio breadth.
• Crescent Pharma: Crescent Pharma is a UK-based generic pharmaceutical company that holds MAs and distributes through UK channels. Similar virtual pharma structure with comparable scale and product portfolio to DAWA.
• Pinewood Healthcare: Pinewood Healthcare is a UK-based generic pharmaceutical company supplying the NHS and UK wholesalers. Operates a similar MAH-driven model with outsourced manufacturing to DAWA.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is one of the world's largest generic pharmaceutical manufacturers with substantial UK operations. Operates in the same UK generic market as DAWA and represents both a competitor and a potential acquirer. Broad incumbent comparable on market and category.
• Sandoz (Novartis division): Sandoz is the global leader in generic pharmaceuticals with significant UK presence. While vastly larger, Sandoz competes in the same UK generic market and could acquire or absorb DAWA's portfolio. Broad incumbent comparable on market and product category.
• Zentiva: Zentiva is a major European generic pharmaceutical company with UK presence. Competes in the same UK generic market and offers comparable products. Broader European scale but same category and customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dawa-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DAWA LIMITED